MedTrace Logo

A Study of HMPL-689 in Healthy Volunteers

NCT02631642 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2017-08-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of a single dose of HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses of HMPL-689 in healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

HMPL-689

selective PI3Kδ inhibitor

DRUG

HMPL-689 placebo

placebo of HMPL-689

Sponsors & Collaborators

  • Hutchison Medipharma Limited

    lead INDUSTRY

Principal Investigators

  • Jason Lickliter · Nucleus Network Ltd

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-23
Primary Completion
2016-10-26
Completion
2017-02-28

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02631642 on ClinicalTrials.gov